natgillin/translations-raw huggingface dataset:
Interaction with other medicinal products and other forms of interaction: No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product other than Versiguard Rabies and Versican Plus L4.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Ni podatkov o varnosti ter učinkovitosti ob uporabi tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini razen za Versiguard Rabies in Versican Plus L4.
The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine distemper virus, canine parvovirus, canine adenovirus Types 1 and 2, and canine parainfluenza virus.
Cepivo je namenjeno aktivni imunizaciji zdravih pasjih mladičev in odraslih psov proti boleznim, ki jih povzročajo virus pasje kuge, pasji parvovirus, pasji adenovirus tipa 1 in 2 in virus pasje parainfluence.
However, the vaccine has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to CDV, CAV and CPV at levels equal or higher to those likely to be encountered under field conditions.
Dokazano je, da je cepivo učinkovito ob prisotnosti maternalnih protiteles za CDV, CAV in CPV ob ravneh, ki so enake ali višje, kot jih običajno srečamo v terenskih pogojih.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: V primeru nenamernega samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
50 x 1 dose
25 x 1 odmerek 50 x 1 odmerek
Shake well and immediately inject the entire contents (1 ml) of the reconstituted product.
Pred uporabo dobro pretresite in takoj injicirajte živali celotno rekonstituirano vsebino (1 ml).
Canine adenovirus Type 2
Pasji adenovirus tipa 2
Lyophilisate: Trometamol Edetic acid Sucrose Dextran 70
Liofilizat: trometamol edetna kislina saharoza dekstran 70
EXPIRY DATE EXP {month/year}
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP {mesec/leto}
Once mixed, the contents of the vial should appear a pink/red or yellowish colour with a slight opalescence.
Po mešanju mora vsebina viale izgledati rožnato/rdeče ali rumenkaste barve z rahlo opaloscenco.
− 3 weeks after completion of the primary course for CPiV.
− 3 tedne po zaključku osnovnega cepljenja proti CPiV.
SPECIAL STORAGE CONDITIONS Store and transport refrigerated.
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte in prevažajte v hladilniku.
Incompatibilities: Do not mix with any other veterinary medicinal product other than those mentioned above.
Ne mešajte z nobenimi drugimi zdravili za uporabo v veterinarski medicini razen s tistimi navedenimi zgoraj.
Although the efficacy of the rabies fraction has been demonstrated following administration at 12 weeks, at the discretion of the veterinary surgeon, in case of need, dogs younger than 8 weeks can be vaccinated with Versican Plus DHPPi mixed with Versiguard Rabies as the safety of this association has been demonstrated in 6 week old dogs.
Čeprav je bila učinkovitost komponente proti steklini dokazana pri dajanju v starosti 12 tednov, se v primeru, da je to potrebno in ob presoji veterinarja, s cepivom Versican Plus DHPPi, ki se ga zmeša s cepivom Versiguard Rabies lahko cepi pse, mlajše od 8 tednov, ker je bila varnost te kombinacije v starosti 6 tednov pri psih dokazana.
Dosage and route of administration:
Odmerjanje in pot uporabe:
First dose: Versican Plus DHPPi from 8-9 weeks of age.
Prvi odmerek: Versican Plus DHPPi od starosti 8-9 tednov naprej.
At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2 and canine parvovirus.
Vsaj tri leta po osnovnem cepljenju proti virusu pasje kuge, pasjemu adenovirusu tipa 1, pasjemu adenovirusu tipa 2 in pasjemu parvovirusu.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 04/07/2014.
Datum pridobitve dovoljenja za promet: 04.07.2014.
Second dose: Versican Plus DHPPi mixed with Versiguard Rabies 3-4 weeks later, but not before 12 weeks of age.
Drugi odmerek: Versican Plus DHPPi zmešamo z Versiguard Rabies 3-4 tedne kasneje, vendar ne pred starostjo 12 tednov.
In case of travelling to risk areas or outside the EU, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of ≥ 0.5 IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres ≥ 0.5 IU/ml).
V primeru potovanja na območja z večjim tveganjem ali izven EU se lahko veterinarji odločijo za dodatna cepljenja proti steklini po 12. tednu starosti, da zagotovijo titer protiteles v višini ≥ 0,5 i.e./ml, ki na splošno velja za učinkovito zaščito in obenem izpolnjuje zahteve za potovanje živali (titer protiteles ≥ 0.5 i.e./ml).
Lyophilisate and solvent for suspension for injection.
Liofilizat in vehikel za suspenzijo za injiciranje.
Reconstituted vaccine: whitish to yellowish colour with a slight opalescence.
Rekonstituirano cepivo: belkaste do rumenkaste barve, rahlo opalescentno.
Name and address of the manufacturer of the biological active substances
Ime in naslov proizvajalca(proizvajalcev) biološke (bioloških) učinkovine (učinkovin)
Manufacturer responsible for batch release:
BELGIJA Proizvajalec odgovoren za sproščanje serij:
Canine distemper virus, strain CDV Bio 11/A
Virus pasje kuge, sev CDV Bio 11/A
Aseptically reconstitute the lyophilisate with the solvent.
Aseptično rekonstituirajte liofilizat z vehiklom.
STATEMENT OF ACTIVE SUBSTANCES Each dose of 1 ml contains:
Vsak odmerek po 1 ml vsebuje:
Rabies:
Steklina:
Revaccination scheme:
Ponovno cepljenje:
Plastic box containing 25 vials (1 dose) of lyophilisate and 25 vials (1 ml) of solvent.
Plastična škatla s 25 vialami (s po 1 odmerkom) liofilizata in 25 vialami (po 1 ml) vehikla.
The contents of a single vial of Versican Plus DHPPi should be reconstituted with the contents of a single vial of Versiguard Rabies (instead of the solvent).
Vsebino 1 viale zdravila Versican Plus DHPPi je treba rekonstituirati z vsebino 1 viale zdravila Versiguard Rabies (namesto vehikla).
− to prevent mortality and clinical signs caused by canine adenovirus type 1,
− za preprečevanje smrtnosti in kliničnih znakov, ki jih povzroča pasji adenovirus tipa 1,
Plastic box containing 50 vials (1 dose) of lyophilisate and 50 vials (1 ml) of solvent.
Plastična škatla s 50 vialami (s po 1 odmerkom) liofilizata in 50 vialami (po 1 ml) vehikla.
Canine parvovirus Type 2b, strain CPV-2b Bio 12/B
Pasji parvovirus tipa 2b, sev CPV-2b Bio 12/B
Canine parvovirus Type 2b
Pasji parvovirus tipa 2b
If protection against Leptospira is required dogs can be vaccinated with two doses of Versican Plus DHPPi mixed with Versican Plus L4 3-4 weeks apart from 6 weeks of age: The contents of a single vial of Versican Plus DHPPi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent).
Če je potrebno pse zaščititi pred leptospirozo jih lahko cepimo z dvema odmerkoma Versican Plus DHPPi, ki ga zmešamo z Versican Plus L4 v razmaku 3-4 tednov od starosti 6 tednov naprej: Vsebino 1 viale zdravila Versican Plus DHPPi je treba rekonstituirati z vsebino 1 viale zdravila Versican Plus L4 (namesto vehikla).
Type I glass vial containing 1 dose of lyophilisate closed with a bromobutyl rubber stopper and aluminium cap.
Viala iz stekla tipa I, ki vsebuje 1 odmerek liofilizata, zaprta z zamaškom iz brombutilne gume in aluminijasto zaporko.
Type I glass vial containing 1 ml of solvent closed with a chlorobutyl rubber stopper and aluminium cap.
Viala iz stekla tipa I, ki vsebuje 1 ml vehikla, zaprta z zamaškom iz klorobutilne gume in aluminijasto zaporko.
Pack sizes:
Velikosti pakiranja:
PARTICULARS TO APPEAR ON THE OUTER PACKAGE BOX
PODATKI NA ZUNANJI OVOJNINI ŠKATLA
− to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus.
− za preprečevanje kliničnih znakov (izcedek iz smrčka in oči) in zmanjšanje izločanja virusa, ki jih povzroča virus pasje parainfluence.
Lyophilisate (live attenuated):
Učinkovina(e): Liofilizat (živi, atenuirani):
Canine adenovirus Type 2, strain CAV-2 Bio 13
Pasji adenovirus tipa 2, sev CAV-2 Bio 13
− to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,
− za preprečevanje kliničnih znakov in zmanjšanje izločanja virusa, ki jih povzroča pasji adenovirus tipa 2,
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
PROIZVAJALEC (PROIZVAJALCI) BIOLOŠKE (BIOLOŠKIH) UČINKOVINE (UČINKOVIN) IN PROIZVAJALEC (PROIZVAJALCI) ZDRAVILA, ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
Special warnings for each target species:
POSEB NO(A) OPOZORILO(A) Posebna opozorila za vsako ciljno živalsko vrsto:
− to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus, and
− za preprečevanje kliničnih znakov, levkopenije in izločanja virusa, ki jih povzroča pasji parvovirus, in
Primary vaccination scheme: Two doses of Versican Plus DHPPi 3-4 weeks apart from 6 weeks of age.
Osnovno cepljenje: Dva odmerka cepiva Versican Plus DHPPi v razmaku 3-4 tednov od starosti 6 tednov naprej.
Some animals may also not show titres > 0.5 IU/ml after the primary vaccination.
Posamezne živali lahko ne dosežejo titra protiteles proti virusu stekline v višini ˃ 0,5 i.e./ml, po prvem cepljenju.
Canine parainfluenza Type 2 virus
Virus pasje parainfluence tipa 2
Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15
Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15
EXP {month/year} Once reconstituted, use immediately.
Rekonstituirano zdravilo uporabite takoj.
− to prevent mortality and clinical signs caused by canine distemper virus,
− za preprečevanje smrtnosti in kliničnih znakov, ki jih povzroča virus pasje kuge,
SPECIAL WARNING(S)
INDIKACIJA(E)
No other adverse effects other than those mentioned under “Adverse reactions” have been observed after administration of a 10-fold overdose of the vaccine.
Po dajanju 10-krat prevelikega odmerka cepiva ni bilo opaziti drugih neželenih učinkov, razen tistih, navedenih v poglavju »Neželeni učinki«.
The live attenuated virus vaccine strains CAV-2, CPiV and CPV-2b may be shed by vaccinated dogs following vaccination, shedding of CPV has been shown for up to 10 days.
Cepljeni psi lahko po cepljenju izločajo žive atenuirane vakcinalne seve CAV-2, CPiV in CPV-2b.
PACKAGE LEAFLET: Versican Plus DHPPi lyophilisate and solvent for suspension for injection for dogs
Versican Plus DHPPi liofilizat in vehikel za suspenzijo za injiciranje za pse
Once mixed, the contents of the vial should appear a whitish to yellowish colour with a slight opalescence.
Po mešanju mora vsebina viale izgledati belkasto do rumenkasto z rahlo opaloscenco.
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription.
POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
Onset of immunity:
Nastop imunosti:
MARKETING AUTHORISATION HOLDER
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET
NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi lyophilisate and solvent for suspension for injection for dogs
NAVODILO ZA UPORABO Versican Plus DHPPi liofilizat in vehikel za suspenzijo za injiciranje za pse
Minimum Maximum
Najmanj
Name and address of the manufacturer responsible for batch release
Ime in naslov proizvajalca(proizvajalcev) zdravila, odgovornega (odgovornih) za sproščanje serij Bioveta, a.s.,
Canine distemper virus
Virus pasje kuge
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each dose of 1 ml contains:
Vsak odmerek po1 ml vsebuje:
Lyophilisate: spongy matter of white colour.
Liofilizat: bela gobasta snov.
Active substances:
Osnovno cepljenje:
STATEMENT OF THE MRLs Not applicable.
NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA ( MRL)
NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi solvent for dogs
Versican Plus DHPPi vehikel za pse
QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
KAKOVOSTNA IN KOLIČINSKA SESTAVA
103.6 TCID50
4.11 Karenca
Immediate Packaging Pack size
Stična ovojnina Velikost pakiranja
The MAM should be prepared fresh daily.
MAM se mora pripravljati dnevno sveža.
Appropriate treatment and equipment should be readily available.
Ustrezno zdravljenje in oprema morajo biti takoj na voljo.
Continue until a solid residue remains.
Nadaljujte dokler ne ostane ostanek.
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http://www.emea.europa.eu/.
A separate cannula should be used.
Uporabljati moramo ločeno kanilo.
Higher doses might be justified in some clinical
Višje doze so lahko upravičene v nekaterih kliničnih
Incubate for 10 minutes in this condition.
V tem stanju inkubirajte 10 minut.
- If you have any further questions, ask your doctor.
• Če imate dodatna vprašanja, se posvetujte z zdravnikom.
The product label includes the appropriate storage conditions and the expiry date for the product.
Signatura na izdelku vključuje ustrezne pogoje shranjevanja in datum izteka roka uporabnosti izdelka.
• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
• POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
Use aseptic technique throughout.
Vseskozi uporabljajte aseptično tehniko.
Swirl gently for 10 seconds in order to ensure complete dissolution of the powder.
Nežno vrtinčite 10 sekund da zagotovite popolno raztapljanje praška.
Equipment and Materials
Oprema in materiali
below)
spodaj)
See section 4.4
Glejte poglavje 4.4.
Pregnancy and lactation.
Nosečnost in dojenje.
Treatment of an overdose should be directed towards the support of vital functions.
Zdravljenje prevelikega odmerka mora biti usmerjeno na podpiranje življenskih funkcij.
Any woman who has missed a period should be assumed to be pregnant until proven otherwise.
Vsako žensko, ki ji je izostala menstruacija, moramo šteti za nosečo, dokler se ne dokaže drugače.
A value of at least 90% should be obtained in a satisfactory preparation.
Za zadovoljivo pripravo mora doseči vrednost A najmanj 90%.
91192 GIF sur YVETTE cedex FRANCE
91192 GIF sur YVETTE cedex FRANCIJA
The peptide itself has a lower affinity for these receptors.
Peptid sam po sebi ima nižjo afiniteto za te receptorje.
Instructions for reconstitution, handling and disposal are given in section 12.
Navodila za rekonstitucijo, ravnanje in odlaganje so navedena v poglavju 12.
Trained hospital staff will ensure the correct storage of NeoSpect.
Šolano bolnišnično osebje, bo zagotovilo pravilno shranjevanje NeoSpecta.
(The saturated sodium chloride solution can be reused.
(Nasičeno raztopino natrijevega klorida se lahko ponovno uporabi.
Toxic effects observed in the animal studies were not considered to be relevant in clinical use in humans.
Smatra se, da škodljivi učinki opaženi v študijah na živalih, niso relevantni za klinično uporabo pri človeku.
It tells you about your medicine.
Vsebuje podatke o vašem zdravilu.
If any of the above mentioned conditions are applicable to you, you should inform your doctor.
Če katerokoli od navedenih stanj velja za vas, morate o tem obvestiti svojega zdravnika.
Percent 99mTc-depreotide: 100 - (A + B).
Odstotni delež 99mTc-depreotida: 100 - (A+B).
In the same prevalence range the positive predictive value was in the range 52-72%.
Pri istem razponu prevalence je bila pozitivna napovedna vrednost 52-72%.
The ammonium acetate solution can be used for up to one month.
Raztopino amonijevega acetata lahko uporabljate do mesec dni.
The vial should not be cooled under running water, as this may impede labelling.
Viale ne smete ohladiti pod tekočo vodo, ker to lahko poškoduje označevanje.
Repeat administration must be avoided.
Večkratni uporabi se moramo izogibati.
Unlabelled NeoSpect should not be administered directly to the patient.
Neoznačenega NeoSpecta se ne sme dajati direktno bolniku.
Allow the vial to cool to body temperature (about 15 minutes) at room temperature before proceeding.
Pustite, da se viala ohladi na telesno temperaturo (približno 15 minut) pri sobni temperaturi preden nadaljujete.
All were uncommon (0.1%-1%) in occurrence.
Vsi neželeni učinki so se pojavljali redko (0,1% -1%).
The use of NeoSpect does involve exposure to small amounts of radioactivity, however your doctor will always consider the possible risks and benefits when considering the use of this product.
Uporaba NeoSpecta vključuje izpostavljenost majhni količini radioaktivnosti, vendar bo vaš zdravnik vedno pretehtal možno tveganje in koristi, ko bo presojal o uporabi tega izdelka.
Alternative techniques, which do not involve ionising radiation, should be considered.
Razmisliti moramo o uporabi alternativnih tehnik, ki ne vključujejo ionizirajočega sevanja.
This scan will show exactly the distribution of the radioactivity within the body.
Ta slika bo natančno pokazala porazdelitev radioaktivnosti v telesu.
One to 18% of the injected dose of radioactivity appeared in the urine at 4 hours after injection.
Ena do 18% injicirane doze radioaktivnosti se pojavi v urinu 4 ure po injekciji.
Studies have not been conducted to evaluate carcinogenic potential or effects on fertility.
Študije za oceno karcinogenega potenciala ali učinkov na plodnost niso izvedene.
Re-administration: Clinical data reflecting safety and efficacy of multiple injections are only available in 13 patients.
Ponovna uporaba: O varnosti in učinkovitosti večkratnih injekcij so na voljo klinični podatki za samo 13 bolnikov.
The radioactive amount of the diluted generator eluate must not exceed 1.8 GBq when it is added to the vial.
Količina radioaktivnosti razredčenega eluata iz generatorja ne sme preseči 1,8 GBq, ko se ga dodaja v vialo.
After use, dispose of as radioactive waste.
Po uporabi odstranite kot radioaktivne odpadke.
For a full list of excipients, see section 6.1
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Patients with a negative FNA should be followed up clinically as some FNA biopsies may give false negative results.
Bolnike z negativnim FNA izvidom je treba klinično spremljati, ker lahko nekatere FNA biopsije dajo lažne negativne rezultate.
Experience from clinical trials indicates that no dose adjustment is required.
Izkušnje iz kliničnih študij kažejo, da prilagajanje odmerka ni potrebno.
Its receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licenses of the local competent official organisations.
Prevzem, shranjevanje, uporaba, prenos in odlaganje so predmet predpisov in/ali ustreznih
Count each strip section in a dose calibrator and interpret the results as follows:
Odčitajte štetje za vsak kos traku v kalibratorju odmerka in interpretirajte rezultate kot sledi:
Because the substance contains a small amount of radioactivity it can be detected from outside the body using special cameras, and a picture, known as a scan, can be taken.
Ker vsebuje spojina majhno količino radioaktivnosti, jo lahko zaznamo zunaj telesa z uporabo posebnih kamer in lahko posnamemo sliko, znano kot sken (pregledni posnetek).
It will only be handled and administered by people who are trained and qualified in the safe handling of radioactive material.
Z njim bo ravnalo in ga uporabljalo samo osebje, ki je izšolano in usposobljeno za varno rokovanje z radioaktivnimi snovmi.
Diagnostic agent for scintigraphic imaging.
Diagnostično sredstvo za scintigrafsko slikanje.
For each patient, exposure to ionising radiation must be justifiable on the basis of the likely benefit.
Pri vsakem bolniku mora biti izpostavljanje ionizirajočem sevanju upravičeno glede na verjetne koristi.
Because there are strict laws covering the use, handling and disposal of radioactivity, NeoSpect will always be used in a hospital or a similar setting.
Ker so predpisi, ki urejajo uporabo, ravnanje in odstranjevanje radioaktivnosti strogi, se bo NeoSpect vedno uporabljal samo v bolnišnicah ali podobnih ustanovah.
In view of the false negative rate of FNA (5-8% false negative rate reported), thoracotomy is considered to be the gold standard.
Glede na odstotek lažnih negativnih rezultatov pri FNA (poročajo o 5-8% lažno negativnih rezultatov), velja torakotomija za zlati merilo.
Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo,
The values are listed in descending order as mGy/MBq and assume urinary bladder emptying at 4.8 hours.
Vrednosti so navedene v padajočem vrstnem redu kot mGy/MBq in predvidevajo praznenje sečnega mehurja v 4,8 urah.
For most diagnostic investigations using nuclear medicine procedures, the radiation dose delivered (effective dose equivalent) is less than 20 mSv.
Pri večini diagnostičnih preiskav z uporabo nuklearnih medicinskih postopkov je prejeta doza sevanja (ekvivalent učinkovite doze) manjša od 20 mSv.
NeoSpect is for use in patients over the age of 18 years.
NeoSpect je namenjen za uporabo pri bolnikih starejših od 18 let.
Estimated absorbed radiation dose Target Organ mGy/MBq
Ocena absorbirane doze ionizirajočega sevanja Izpostavljeni organ mGy/MBq
18 months.
6.3 Rok uporabnosti 18 mesecev.
Total clearance averaged 2 to 4 ml/min/kg.
Celotni očistek je bil povprečno 2 do 4 ml/min/kg.
Radiopharmaceuticals should be prepared by the user in a manner which satisfies both radiation safety and pharmaceutical quality requirements.
Radiofarmacevtske izdelke mora uporabnik pripravljati tako, da ustrezajo zahtevam o varnosti sevanja in zahtevam o farmacevtski kakovosti.
This radiopharmaceutical may be handled only by authorised persons in designated clinical settings.
S tem radiofarmacevtskim izdelkom smejo ravnati samo pooblaščene osebe v pooblaščenih kliničnih ustanovah.
Following reconstitution and radiolabelling, the material must be used within 5 hours as radiochemical purity and stability have been demonstrated for 5 hours at 25°C.
Po rekonstituciji in radioaktivnem označevanju se mora raztopina uporabiti v 5 urah, ker sta bili radiokemična čistost in stabilnost dokazani za 5 ur pri 25°C.
Storage of radiopharmaceuticals should be in accordance with national regulations on radioactive
Shranjevanje radiofarmacevtskih izdelkov mora biti v skladu z lokalnimi predpisi o radioaktivnih snoveh.
Add distilled water up to the 50 ml mark, mix thoroughly.
Dodajte destilirano vodo do oznake 50 ml, temeljito premešajte.
Solid sodium chloride should remain at the bottom of the jar; if there is no residue, add more solid sodium chloride and shake again for 10 to 15 minutes.
Trdni natrijev klorid mora ostati na dnu posode; če ni ostanka, dodajte še natrijevega klorida in ponovno stresajte 10 do 15 minut.
After use, the container and any unused material must be disposed of as radioactive waste in
Po uporabi, se mora vsebnik in ves neporabljen material zavreči kot radioaktvne odpadke v skladu z
- if you are allergic (hypersensitive) to depreotide or any of the other ingredients of NeoSpect or - if there is any possibility that you are pregnant.
Če ste alergični na (preobčutljivi za) depreotid ali katerokoli sestavino zdravila NeoSpect ali na Če obstaja kakršnakoli možnost, da ste noseči.
You should tell your doctor if there is any possibility that you are pregnant, or if you are breast
Zdravnika morate obvestiti, če obstaja kakršnakoli možnost, da ste noseči ali če dojite.
The effective dose (ED) calculated in accordance with ICRP Publication 60 (Pergamon Press, 1991) gave a value of 0.016 mSv/MBq, corresponding to 11.84 mSv after
Učinkovitadoza (ED), izračunana v skladu z ICRP Publication 60 (Pergamon Press, 1991), je dala vrednost 0,016 mSv/MBq, kar ustreza 11,84 mSv po dajanju 740 Mbq.